Name of this trial: OptimUM-10
What type of cancer is this for? Uveal Melanoma
Who is this trial for? Subjects with Primary Non-metastatic Uveal Melanoma
What biomarkers are involved? Monosomy 3
What is the National Clinical Trial #? NCT07015190; https://clinicaltrials.gov/study/NCT07015190
Brief summary of this trial: A Randomized, Phase 3, Open-label Study of Neoadjuvant Darovasertib in Subjects with Primary Non-metastatic Uveal Melanoma
Need to know: Must be at high risk of metastasis defined by at least one of the following: Monosomy 3, Class 2 GEP, Stage 3 by AJCC. Must not have had previous treatment for uveal melanoma or have evidence of metastatic uveal melanoma.
Where is this trial available? The Cancer & Hematology Centers and other sites nationwide, please click on link above to review.
For more information, please call 800-411-7999 or email clinicaltrials@thechc.com